FDA: Product quality issues fuel rise in drug shortages

"A very large number of quality product issues" is what Valerie Jensen, associate director for FDA's drug shortage program (CDER), cites as the major cause of the 178 shortages counted by the regulator in 2010. To be precise, product quality played a role in 54% of shortages. Some of the issues were sterility or impurities; others were production delays or capacity problems. "In 2011, we're seeing the same trend." Story

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot.